SHINE Technologies

Janesville,  WI 
United States
https://shinemed.com

• Booth: 36

Dedicated to being the world’s top medical isotope producer through fusion technology.

SHINE is a next-generation nuclear technology company, focused on deploying state-of-the-art fusion technology to help solve global problems and create a scalable path toward practical fusion energy. SHINE deploys its safe, cost-effective and environmentally-friendly technology in a step-wise approach, beginning with our systems used for advanced industrial imaging in non-destructive testing of components used in aerospace, defense, transportation, energy and other sectors. SHINE’s proprietary medical isotope production creates Molybdenum 99 and non-carrier-added Lutetium 177 used in tens of thousands of daily procedures to diagnose and treat heart disease and late-stage cancer. For more information, follow SHINE on Facebook, LinkedIn and Twitter.

 Press Releases

• SHINE Announces Chris Vessell as General Manager of Therapeutics Division (Jun 03, 2022)

  Health Care Industry Veteran to Lead Growing Team and Nuclear Medicine Offering

  JANESVILLE, Wis., – SNMMI  2022 Booth # 36 – May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.

  Vessell brings more than 25 years of experience in health care, manufacturing and financial services to SHINE, including a Six Sigma Master Black Belt Certification for his leadership, service and team management. He most recently served as the U.S. Nuclear Medicine Supply Chain Leader for GE Healthcare’s Pharmaceutical Diagnostics group (PDx), where he oversaw the production of various radio-pharmaceutical products from cyclotron production of raw material through final drug formulation. In addition, he was also responsible for leading PDx’s network of 31 radiopharmacies across the U.S. prior to their divesture, successfully delivering more than 2 million nuclear medicine prescription patient doses to hospital and clinic partners on an annual basis.

• SHINE Technologies and ImaginAb Announce Lutetium-177 Clinical Supply Agreement (Jun 03, 2022)

  JANESVILLE, Wis., – SNMMI  2022 Booth # 36 – Mar. 9, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and ImaginAb Inc. (ImaginAb), a market-leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the signing of a clinical supply agreement. Under the terms of this agreement, SHINE will provide ImaginAb with highly pure, non-carrier-added lutetium-177 (Lu-177) to support the company’s preclinical and clinical needs in the development of RPTs targeting various cancers.

  SHINE’s Therapeutics division produces n.c.a. Lu-177, a low-energy beta-particle emitter, which can be paired with a targeting molecule (such as an antibody or peptide) to directly target and irradiate cancer cells. SHINE’s fusion technology and proprietary medical isotope production is expected to scale without supply chain limitations experienced recently due to nuclear reactor shutdowns. The result: better meeting the needs of n.c.a. Lu-177 based therapies as they commercialize.

  ImaginAb is developing radiopharmaceutical therapy agents based on proprietary minibody and cys-diabody platform technologies. This platform possesses the highly tumor target selective features of larger antibodies while offering highly tunable pharmacokinetics providing rapid clearance from non-target tissues.

• SHINE and Telix Pharmaceuticals Announce Lutetium-177 Clinical Supply Agreement (Jun 03, 2022)

  SHINE to supply n.c.a. Lu-177 for the clinical development of Telix’s investigational radiopharmaceuticals, TLX591 and TLX250

  JANESVILLE, Wis., – SNMMI  2022 Booth # 36 – Feb. 10, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.

  SHINE will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the US market.

  Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, “SHINE’s investment in high quality isotope production places them at the forefront of the radiopharmaceutical supply chain with particular strength in servicing the US market. The agreement with SHINE supports our goal to establish a global supply chain with the capacity and reliability to support an increasing level of clinical activity through Telix-sponsored and investigator-led studies and to scale-up to commercial stage.”

• SHINE Europe B.V. Designing Advanced Medical Isotopes Facility in the Netherlands (Jun 03, 2022)

  A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale

  Veendam, Netherlands, – SNMMI  2022 Booth # 36 – February 2 – SHINE Europe B.V. (SHINE Europe), a subsidiary of SHINE Technologies, LLC, (SHINE), a next-generation nuclear technology company, today announced the company has secured funding to begin designing an advanced medical isotopes facility in Veendam, the Netherlands.

  This new facility will leverage SHINE’s innovative production systems to safely produce medical isotopes including molybdenum-99 (Mo-99), which is currently used in millions of diagnostic imaging procedures each year to help diagnose various life-threatening diseases in patients across the globe. The new facility is expected to develop medical isotopes in a very reliable, environmentally-friendly and less wasteful process than the legacy methods, also without adding exponential taxpayer burden to construct new European reactors.

  SHINE Europe marks the second such nuclear facility for the company as SHINE’s Janesville, Wis (U.S.A.) plant also plans to begin the production of Mo-99. SHINE is also exploring potential production of additional isotopes such as iodine-131 and xenon-133, among others. Once SHINE Europe is fully operational, SHINE anticipates the two facilities’ combined output of Mo-99 can serve up to 70 percent of the global need for Mo-99 used in daily diagnostic imaging.

• SHINE and Department of Energy Sign First-ever Contracts Under Uranium Lease and Take-back Program for Molybdenum-99 (Jun 03, 2022)

  Vital medical radioisotope used in over 40,000 medical diagnostic procedures in the United States every day

  JANESVILLE, Wis., – SNMMI  2022 Booth # 36 – Jan. 6 – SHINE Technologies LLC (SHINE), a next-generation nuclear technology company, and the Department of Energy’s National Nuclear Security Administration (NNSA) and Office of Environmental Management (DOE-EM) announced signing of the first-ever contracts as part of the Department’s Uranium Lease and Take-back Program. The shared milestone for SHINE and the Department’s efforts will help increase domestic production of molybdenum-99 (Mo-99), a crucial medical radioisotope used in over 40,000 daily medical diagnostic procedures across the United States to assist in diagnosing life-threatening diseases, including heart disease and cancer.

  The NNSA’s lease contract will provide SHINE with the low-enriched uranium necessary to produce Mo-99, while SHINE’s contract with DOE-EM details requirements surrounding the return of any resulting radioactive waste without a commercial disposition path once Mo-99 production is complete.